← MediciNova, Inc. (MNOV) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
MediciNova, Inc. (MNOV)
Pharmaceutical Preparations · market cap $141M · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
6
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
MediciNova (MNOV) is a micro-cap pharmaceutical company with 13 employees and a $67M market cap, developing MN-166 (ibudilast) as its lead asset in a Phase 3 trial for glioblastoma. The company is pre-revenue with ~$27.3M cash (~24 months runway) and a diversified but early-stage pipeline spanning ALS, NASH, asthma, and interstitial cystitis. The pivotal Phase 3 MN-166 GBM readout, estimated around April 2027, is the single defining binary event for the stock.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2026-12-31 (est.)Phase 2 · MN-001imp 7/10
- 2027-04-15 (est.)Phase 3 · MN-166imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| riluzole | Phase 2 | Amyotrophic Lateral Sclerosis |
| MN-001 | Phase 2 | Non-alcoholic Steatohepatitis |
| ibudilast | Phase 2 | Amyotrophic Lateral Sclerosis |
| MN-221 | Phase 2 | Asthma |
| MN-166 | Phase 3 | Glioblastoma |
| MN-001 BID | Phase 2 | Interstitial Cystitis |
Price & technical context
3-month
+14.0%
6-month
+14.8%
12-month
+28.3%
52-wk range
$1.18–$3.45
vs 50-day MA
-5.4%
vs 200-day MA
+8.4%
Realized vol
79.4%
Max drawdown
-52.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MNOV (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.